We are live on ! Find out more
BJDX icon

Bluejay Diagnostics

8 hedge funds and large institutions have $259K invested in Bluejay Diagnostics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more capital invested

Capital invested by funds: $108K → $259K (+$151K)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

33% more funds holding

Funds holding: 68 (+2)

14.84% more ownership

Funds ownership: 6.05%20.89% (+15%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
1
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$157K +$339K +131,000 New
HCM
2
Heights Capital Management
California
$42.5K +$91.6K +35,400 New
BFM
3
Boothbay Fund Management
New York
$32.6K +$70.2K +27,130 New
Bank of America
4
Bank of America
North Carolina
$12.4K +$26.7K +10,337 New
Vanguard Fiduciary Trust
5
Vanguard Fiduciary Trust
Pennsylvania
$12.3K +$26.4K +10,225 New
TRCT
6
Tower Research Capital (TRC)
New York
$2.29K +$460 +178 +10%
LGM
7
L1 Global Manager
$144
CIAM
8
Caitong International Asset Management
Hong Kong
$1 -$5 -2 -67%
SM
9
Sabby Management
Florida
-$52.9K -28,726 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
-$51.8K -28,127 Closed
UBS Group
11
UBS Group
Switzerland
-$228 -124 Closed

BJDX Hedge Fund Activity: Q2 2026 in Review

8 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q2 2026, worth a combined $259K — up 140% from $108K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BJDX positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $339K. The largest seller was Sabby Management, exiting entirely with an estimated $52.9K sold.

  • 8 institutional investors held Bluejay Diagnostics (BJDX) as of Q2 2026, up from 6 in Q1 2026.
  • Funds reported $259K of Bluejay Diagnostics stock for Q2 2026, up 140% quarter-over-quarter.
  • 5 funds opened new Bluejay Diagnostics positions in Q2 2026 and 3 closed out, a net change of +2 holders.
  • The largest Bluejay Diagnostics buyer in Q2 2026 was Armistice Capital, an estimated $339K added.
  • The largest Bluejay Diagnostics seller in Q2 2026 was Sabby Management, an estimated $52.9K sold.

Based on aggregated 13F filings for Q2 2026.